REG - IXICO plc - Appointment of Independent Non-Executive Director

IXICOAnnouncement

05/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE7310Oa&default-theme=true

RNS Number : 7310O  IXICO plc  05 October 2023

5 October 2023

 

IXICO plc

("IXICO" or the "Company")

 

Appointment of Independent Non-Executive Director

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, is pleased to announce the appointment of
Dr Dipti Amin as an Independent Non-Executive Director of the Company with
immediate effect.

Dr Amin is an experienced non-executive director and medically trained senior
executive with extensive commercial, leadership and operational experience, in
medicine, pharmacology and the highly regulated healthcare and research
sectors.

Dr Amin spent over twenty years of her executive career at IQVIA, occupying
senior positions in compliance, drug safety and medical affairs and will bring
significant additional pharmaceutical and CRO experience to the Company.

Dr Amin currently sits on the Boards of the University of Hertfordshire and
Lineage Cell Therapeutics, a US based biotechnology company, having previously
sat on the Boards of companies in both the private and public sectors.

Dr Amin will also be joining the Remuneration and Audit committees with
immediate effect.

 

Charles Spicer, Chair of IXICO, commented:

 

"We are delighted to welcome Dipti to our Board and look forward to
benefitting from her broad and deep experience of both the pharmaceutical and
CRO sectors."

 

 

 For further information please contact:

IXICO plc                                                                           +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Securities PLC (Nominated adviser and sole broker)                        +44 (0) 20 7397 8900
 Giles Balleny / Charlie Combe (Corporate Finance)
 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 About IXICO

 IXICO is dedicated to delivering insights in neuroscience to help transform
 the advancement of investigational therapies for neurological diseases, such
 as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
 Company's purpose is to advance medicine and human health by turning data into
 clinically meaningful information, providing valuable new insights in
 neuroscience by supporting pharmaceutical companies across all phases of CNS
 clinical research. IXICO's goal is to be a leading advocate of artificial
 intelligence in medical image analysis.

 IXICO has developed and deployed breakthrough data analytics, at scale,
 through its remote access technology platform, to improve the return on
 investment in drug development and reduce risk and uncertainty in clinical
 trials for the Company's pharmaceutical clients.

 More information is available on www.IXICO.com (http://www.IXICO.com) and
 follow us on Twitter @IXICOnews

 Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dipti Mahendra Amin
 (Patel), aged 59, holds or has held the following directorships or
 partnerships in the past five years:

Current                       Previous

 Lineage Cell Therapeutics     Buckinghamshire Healthcare NHS Trust Cambridge Innovation Capital Limited

 University of Hertfordshire   Maaya Associates Limited

 

 Dr Amin does not currently hold any shares in the Company.

 There is no further information required to be disclosed in respect of the
 above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for
 Companies.

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

 

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dipti Mahendra Amin
(Patel), aged 59, holds or has held the following directorships or
partnerships in the past five years:

 

 Current                       Previous

 Lineage Cell Therapeutics     Buckinghamshire Healthcare NHS Trust Cambridge Innovation Capital Limited

 University of Hertfordshire   Maaya Associates Limited

 

 

Dr Amin does not currently hold any shares in the Company.

 

There is no further information required to be disclosed in respect of the
above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for
Companies.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPGRPUUPWGQC